Table 1.
Participant Characteristics.a
| Training Group (n = 47) | Control Group (n = 44) | P | |
|---|---|---|---|
| Age (years) | 72.9 (6.0) | 73.6 (5.3) | .488 |
| Gender, male/female | 28 (60) / 19 (40) | 23 (51) / 22 (49) | .200 |
| Body weight (kg) | 75.8 (14.1) | 76.4 (13.9) | .955 |
| Body height (cm) | 171.8 (9.2) | 171.2 (9.0) | .922 |
| H&Y stage, 2/3 | 20 (43) / 27 (57) | 19 (43) / 25 (57) | 1.000 |
| UPDRS motor | 36 (10) | 37 (11) | .711 |
| PD duration (years) | 6.0 (5.1) | 5.6 (5.0) | .693 |
| Levodopa equivalent dosageb | 581 (295) | 645 (404) | .821 |
| Recurrent faller, yes/noc | 25(53) / 22 (47) | 24 (55) / 20 (45) | .777 |
Abbreviations: H&Y, Hoehn and Yahr; UPDRS, Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease.
a
Continuous data presented as mean (standard deviation) and nominal data as proportions (percentages).
b
Daily levodopa dose equivalency calculated in accordance to Tomlinson et al.29
c
Participants who had experienced ≥2 falls during the previous 12 months were classified as recurrent fallers.